

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/053666 A1

(51) International Patent Classification⁷: **A61K 31/09**,
47/14, 47/24, 47/44

(74) Agent: **ANDRAL, Christophe**; L'OREAL-D.I.P.I, 25-29,
Quai Aulagnier, F-92600 Asnieres (FR).

(21) International Application Number:
PCT/EP2004/014085

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date:
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03/13660 21 November 2003 (21.11.2003) FR
60/541,245 4 February 2004 (04.02.2004) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GAL-
DERMA RESEARCH & DEVELOPMENT, S.N.C.**
[FR/FR]; 635, route des Lucioles, Quartier des Clausonnes,
F-06560 Valbonne Sophia Antipolis (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PITRE, Franck**
[FR/FR]; 26, allée Charles Pathé, F-77600 Bussy Saint
Georges (FR). **FREDON, Laurent** [FR/FR]; Chemin du
Camouyer - Lotissement Les Templiers, Cidex 410 Bis,
F-06330 Roquefort les Pins (FR). **MALLARD, Claire**
[FR/FR]; 1, Rue des Petits Ponts, F-06250 Mougins le
Haut (FR).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

revendiqué prio E1.

in concl. - in invent E1.

(54) Title: **SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES**

(57) Abstract: The invention relates to a composition in the form of a spray comprising a pharmaceutical active agent, which is a derivative of vitamin D, at least one volatile silicone and a nonvolatile oily phase in a physiologically acceptable medium, to the process for preparing it and to its use in cosmetics and in dermatology.

SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES

5 The invention relates to a composition comprising a pharmaceutical active agent, at least one volatile silicone and a nonvolatile oily phase in a physiologically acceptable medium, to the process for preparing it and to its use in cosmetics and in
10 dermatology, the composition making it possible to obtain good penetration of the active agent through the layers of the skin.

 In the field of dermatology and of the formulation of pharmaceutical compositions, those
15 skilled in the art are led to search for compositions which make it possible to release the active agent and to promote its penetration through the layers of the skin in order to improve its effectiveness. The product should also show good cosmeticity and preferably be
20 nonirritant.

 There are currently many topical compositions comprising an active agent and making it possible to promote penetration thereof into the skin by means of the presence in particular of a high content of pro-
25 penetrating glycol. These compositions are formulated in the form of emulsions with a high content of fatty phase, which are commonly called "lipocrems", in the

form of anhydrous compositions which are called
"ointments", in the form of fluid compositions with a
high content of volatile solvents, such as ethanol or
isopropanol, intended for application to the scalp,
5 also called "hair lotions", or else in the form of
viscous O/W emulsions, which are also called "O/W
creams".

O/W creams comprising a corticoid and a high
percentage of propylene glycol (47.5%), sold under the
10 trade mark TEMOVATE® by the company GLAXOSMITHKLINE,
are, for example, known. The stabilizing of a
formulation comprising such a percentage of glycol
makes it necessary to use, in the emulsion, emulsifiers
and stabilizers of the glyceryl stearate or PEG 100
15 stearate type, or alternatively stabilizers or
consistency factors of the white wax or cetostearyl
alcohol type, which result in the formation of a
viscous cream, that is to say a cream with a viscosity
greater than 10 Pa.s (10 000 centipoises, measured with
20 a Brookfield model LVDV II + mobile No. 4 device, at a
rate of 30 rpm for 30 seconds and at a temperature of
25°C ± 3°C). This viscosity therefore makes the product
difficult to apply. These compositions therefore show,
firstly, poor cosmetic acceptability due to their
25 viscosity and, secondly, risks of intolerance caused by
the presence of high proportions of glycol. Those
skilled in the art therefore wish to improve these

parameters, by virtue of the present invention.

In order to facilitate the application of topical compositions comprising a high percentage of pro-penetrating glycol, the applicant has produced, and
5 protected by means of application EP 832647, a lotion, which is a stable formulation of O/W emulsion type, and the viscosity of which is intermediate between hair lotions which are too fluid and have too limited a use, and O/W creams which are too viscous and have a greasy
10 and sticky side to them, while at the same time conserving the pro-penetrating properties of the glycol. These formulae effectively show good penetration of the active agent, but still comprise a high percentage of glycol which can therefore induce a
15 sticky effect or problems of tolerance resulting in moderate acceptability of the product by the patient.

Formulations containing silicone compounds which result in compositions which are pleasant to use are, moreover, known to those skilled in the art. Thus,
20 in US patent 6,538,039, a novel formulation of active agent for transdermal administration has been developed, comprising silicone compounds in order to deposit a film at the surface of the skin. In that application also, the transdermal passage is
25 facilitated by the obligatory presence of absorption promoters, namely, among other compounds mentioned, glycols.

In patent application EP 0966972, the compositions described can be formulated in the form of a spray and comprise an active compound, a silicone gum and a pharmaceutically acceptable excipient. The
5 problem that the invention described in EP 0966972 proposes to solve is that of depositing a substantive film at the surface of the skin, which problem is solved by means of the presence of the silicone gum.

The problem that the present invention here
10 proposes to solve is that of designing a composition for improving the penetration of the pharmaceutical active agent, and its rapidity of penetration over time, in order to improve its therapeutic efficacy, while at the same time avoiding the presence of a high
15 content of glycol. The composition according to the invention should also be easy to use and show a cosmeticity which is acceptable for application to all the regions of the body which may be affected by the pathology.

20 The two applications EP 0966972 and US 6,538,039 represent the prior art closest to the present invention, given the composition of the formulations described. However, on reading this prior art, there is nothing which could prompt those skilled
25 in the art to choose the composition according to the invention in order to obtain good penetration of the active agent incorporated, into the layers of the skin.

In fact, the applicant has found, surprisingly, that the composition comprising, in a pharmaceutically acceptable vehicle:

- 5 a) a therapeutically effective amount of a pharmaceutical active agent,
 - b) at least one volatile silicone,
 - c) a nonvolatile oily phase,
- results in an improvement in penetration of the active agent.

10 The composition of the present invention, while allowing good penetration of the active principles, also shows very good acceptability and tolerance among patients, as described in Examples 8 and 9 of the present invention. It is therefore found
15 that the composition according to the invention is particularly suitable for the treatment of dermatological conditions, and more particularly very suitable for the treatment of psoriasis.

The invention relates more particularly to a
20 composition comprising, in a pharmaceutically acceptable vehicle:

- a) a therapeutically effective amount of a pharmaceutical active agent,
 - b) at least one volatile silicone,
 - 25 c) a nonvolatile oily phase,
- characterized in that the pharmaceutical active agent is a compound derived from vitamin D.


The term "compound derived from vitamin D" is intended to mean compounds which exhibit biological properties similar to those of vitamin D, in particular the properties of trans-activation of vitamin D response elements (VDREs), such as agonist or antagonist activity with respect to receptors for vitamin D or for its derivatives. Compounds derived from vitamin D that are useful according to the invention thus comprise structural analogues, for example bioaromatic analogues. The expression "vitamins D or their derivatives" is intended to mean, for example, the derivatives of vitamin D₂ or D₃, and in particular 1,25-dihydroxy vitamin D₃ (calcitriol).

Among the pharmaceutical active agents derived from vitamin D which can be used according to the invention, mention may be made, by way of non limiting examples, of the compounds described in patent applications EP 1124779, EP 1235824, EP 1235777, WO 02/94754 and WO 03/050067.

Preferably, the vitamin D derivatives according to the invention are the compounds described in patent FR 2785284, incorporated herein by way of reference. They are compounds which are structural analogues of vitamin D and which show selective activity on cell proliferation and differentiation without being hypercalcian-inducing in nature.


These compounds can be represented by general

formula (I) below:




in which:

- 5 - R_1 represents a hydrogen atom, a methyl radical or a radical $-(CH_2)_n-OR_7$,
- R_2 represents a radical $-(CH_2)_n-OR_8$,
- n , R_7 and R_8 having the meanings given below,
- $X-Y$ represents a bond chosen from the bonds of
- 10 formulae (a) to (d) below which can be read from left to right or vice versa:



R_9 and W having the meanings given below,

- R_3 represents the chain of vitamin D_2 or vitamin
- 15 D_3 ,



the dashed lines represent the bond linking the chain to the benzene ring represented in figure

5 (I),

- or R_3 represents a chain having from 4 to 8 carbon atoms substituted with one or more hydroxyl groups, it being possible for the hydroxyl groups to be protected in acetoxy, methoxy or ethoxy,
- 10 trimethylsilyloxy, tert-butyldimethylsilyloxy or tetrahydropyranyloxy form, and optionally, in addition:
- substituted with one or more lower alkyl or cycloalkyl groups and/or
 - substituted with one or more halogen atoms and/or
 - 15 - substituted with one or more groups CF_3 and/or
 - in which one or more carbon atoms of the chain are replaced with one or more oxygen, sulphur or nitrogen atoms, it being possible for the nitrogen atoms to be optionally substituted with lower alkyl radicals and/or
 - 20 - in which one or more single bonds of the chain are replaced with one or more double and/or triple bonds,
 - R_3 being positioned, on the benzene ring, in the position *para* or *meta* to the X-Y bond,
 - R_4 , R_5 and R_6 , two of which may be identical or
 - 25 different, represent a hydrogen atom, a lower alkyl

radical, a halogen atom, a radical $-OR_{10}$ or a polyether radical,

R_{10} having the meaning given below,

- n being 0, 1 or 2,

5 - R_7 and R_8 , which may be identical or different, represent a hydrogen atom, an acetyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical or a tetrahydropyranyl radical,

- R_9 represents a hydrogen atom or a lower alkyl
10 radical,

- W represents an oxygen or sulphur atom, a radical $-CH_2-$ or a radical $-NH-$ which can optionally be substituted with a lower alkyl radical,

- R_{10} represents a hydrogen atom or a lower alkyl
15 radical,

and also the optical and geometrical isomers of said compounds of formula (I), and the salts thereof when $X-Y$ represent a bond of formula (a) and W represents a radical $-NH-$ optionally substituted with a lower alkyl

20 radical.

Among the compounds of formula (I) that are useful in the compositions of the present invention, mention may in particular be made of the following:

1. 6-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-2-
25 methylhepta-3,5-dien-2-ol,
2. 7-[3-(3,4-bishydroxymethylphenoxymethyl)phenyl]-3-ethyloctan-3-ol,

3. 7-{3-[2-(3,4-bishydroxymethylphenyl)ethyl]phenyl}-
3-ethylocta-4,6-dien-3-ol,
 4. 6-{3-[2-(3,4-bishydroxymethylphenyl)ethyl]phenyl}-
2-methylhepta-3,5-dien-2-ol,
 5. 7-{3-[2-(3,4-bishydroxymethylphenyl)vinyl]phenyl}-
3-ethylocta-4,6-dien-3-ol,
 6. 7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
ethyl-3-octanol,
 7. 4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)-
10 phenyl]-3-ethylocta-4,6-dien-3-ol,
 8. (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)-
phenyl]-3-ethylnona-4,6-dien-3-ol,
 9. (E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
ethyloct-4-en-3-ol,
 - 15 10. (E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
ethyloct-6-en-3-ol,
 11. (E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
ethyloct-6-en-4-yn-3-ol,
 12. (4E,6E)-7-[3-(3,4-bishydroxymethylphenoxyethyl)-
20 phenyl]-3-ethylocta-4,6-dien-3-ol,
 13. (E)-7-[3-(3,4-bishydroxymethylphenoxyethyl)-
phenyl]-3-ethylnon-6-en-3-ol,
 14. (E)-7-{3-[(3,4-bishydroxymethylbenzyl)methyl-
amino]phenyl}-3-ethyloct-6-en-3-ol,
 - 25 15. 7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
ethyl-7-methyloctan-3-ol,
- more preferably, the pharmaceutical active agent

incorporated into the composition according to the invention is (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol.

Advantageously, the composition according to
5 the invention comprises between 0.0001 and 20% by weight, relative to the total weight of the composition, of an active agent, preferably between 0.025 and 15% by weight, and more preferably between 0.01 and 5% by weight.


10 Of course, the amount of active agent in the composition according to the invention will depend on the active agent under consideration.

The composition according to the invention will preferably comprise an active agent derived from
15 vitamin D at a concentration of less than 2% by weight of active agent, preferably of between 0.025 and 0.5% by weight. The preferred pharmaceutical active agent according to the invention is (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-
20 3-ol used at a concentration of 0.3% by weight.

The active agents which can be used according to the invention may be used alone or in combination.

According to the invention, the term "volatile silicone" is intended to mean polyorgano-
25 siloxane compounds, which may be cyclic or linear, having a measurable pressure under ambient conditions. The cyclic volatile silicones according to the

invention are polydimethylcyclsiloxanes, i.e. compounds of formula:



5

with n being, on average, between 3 and 6, and preferably n=4 or n=5, generally known as cyclomethicones. The linear volatile silicones according to the invention are linear polysiloxanes
10 such as hexamethyldisiloxane or low molecular weight dimethicones. The linear volatile silicones generally have a viscosity of less than approximately 5 centistokes at 25°Celsius, whereas the cyclic volatile silicones have a viscosity of less than
15 approximately 10 centistokes at 25°Celsius.

Preferred volatile silicones according to the invention are the linear siloxanes, and more preferably hexamethyldisiloxane. By way of example, mention may be made of the product sold by the company DOW CORNING, DC
20 Fluid 0.65cSt.

Advantageously, the composition according to the invention comprises between 25 and 95% by weight, relative to the total weight of the composition, of the volatile silicone, and preferably between 40 and 80% by

weight, and more preferably between 55 and 65% by weight.

According to the invention, the term "nonvolatile oily phase" is intended to mean a variety of nonvolatile oil suitable for a pharmaceutical or cosmetic composition. The nonvolatile oils generally have a viscosity of greater than approximately 10 centipoises at 25°C, and can reach a viscosity ranging up to 1 000 000 centipoises at 25°C. The nonvolatile oily phase can be made up of a large variety of synthetic or natural, silicone or organic oils, a nonexhaustive list of which is given by way of indication.

(a) Esters

Examples of a nonvolatile oil which can be used according to the invention comprise esters of formula $\text{RCO-OR}'$ with R and R', which may be identical or different, representing a linear or branched chain of an alkyl, alkenyl, alkoxycarbonylalkyl or alkoxycarbonyloxyalkyl containing from 1 to 25 carbon atoms, preferably from 4 to 20 carbon atoms. Examples of such esters include isotridecyl isononanoate, PEG-4 diheptanoate, isostearyl neopentanoate, tridecyl neopentanoate, cetyl octanoate, cetyl palmitate, cetyl ricinoleate, cetyl stearate, cetyl myristate, coco dicaprylate/caprate, decyl isostearate, isodecyl oleate, isodecyl neopentanoate, isohexyl neopentanoate,

octyl palmitate, dioctyl malate, tridecyl octanoate, myristyl myristate and octododecanol.

(b) Glyceryl esters of fatty acids

5 The oil may also comprise fatty esters of natural fatty acids, or triglycerides of animal or plant origin. Such examples include, castor oil, lanolin oil, triisocetyl citrate, triglycerides containing from 10 to 18 carbon atoms, caprylic/capric
10 triglycerides, coconut oil, corn oil, cottonseed oil, flax oil, mink oil, olive oil, palm oil, illipe butter, rapeseed oil, soybean oil, sunflower oil, nut oil and equivalent.

15 (c) Fatty acid glycerides

 The oils which are also suitable are synthetic or semi-synthetic glyceryl esters, such as fatty acid mono-, di or triglycerides, which are modified natural oils or fats, for example glyceryl
20 stearate, glyceryl dioleate, glyceryl distearate, glyceryl trioctanoate, glyceryl linoleate, glyceryl myristate, glyceryl isostearate, PEG castor oils, PEG glyceryl oleates, PEG glyceryl stearates, and equivalent.

25


(d) Nonvolatile hydrocarbons

Nonvolatile hydrocarbons such as paraffins,

isoparaffins, mineral oils, and equivalent are also very suitable for the composition according to the invention, as non-volatile nonpolar solvent.

5 (e) Guerbet esters

Guerbet esters are esters resulting from the reaction of a Guerbet alcohol of general formula:



10 and a carboxylic acid of general formula

R3-COOH or HOOC-R3-COOH,


R1 and R2, which may be identical or different, represent an alkyl containing from 4 to 20 carbon atoms, and R3 represents a substituted or unsubstituted
15 fatty radical, such as a linear or branched, saturated or unsaturated alkyl or alkylene chain containing from 1 to 50 carbon atoms, a phenyl, which may be substituted with a halogen, a hydroxyl, a carboxyl, or an alkylcarbonylhydroxyl.

20

(f) Silicone oils

The silicone oils which can be used according to the invention for making up the nonvolatile phase are polyorganosiloxane compounds having a measurable
25 pressure under ambient conditions and a viscosity strictly greater than 10 centistokes and lower than 20

centistokes. The nonvolatile silicones which can be used according to the invention are the compounds of formula:



with n strictly greater than 6.

The preferred nonvolatile oily phase according to the invention is paraffin oil.

Advantageously, the composition according to
10 the invention comprises between 1 and 50% by weight, relative to the total weight of the composition, of nonvolatile oily phase, preferably between 5 and 30% by weight, and more preferably between 7 and 15% by weight.

15 According to a preferred embodiment of a composition according to the invention, the composition also comprises a silicone gum. The applicant has, in fact, discovered, surprisingly, that a composition comprising a silicone gum in the concentrations defined
20 hereinafter shows more rapid penetration of the active agent through the various layers of the skin.

The term "silicone gums" is intended to mean the silicone gums known to those skilled in the art, and in particular those described in patent application

EP 0966972, incorporated herein by way of reference. According to this preferred embodiment of a composition according to the invention, the silicone gum is introduced at a concentration of between 0.001 and 3%
5 by weight, preferably between 0.01 and 1% by weight. Dow Corning provides a commercial product sold under the name DC Silmogen Carrier, which is made up of 99% of hexamethyldisiloxane and 1% of silicone gum, which product may advantageously be used in one of the
10 compositions according to the invention.

The pharmaceutically acceptable vehicle according to the invention should be chosen such that the advantageous properties intrinsically associated with the present invention are not, or are not
15 substantially, altered by the envisaged addition. Preferably, the vehicle used according to the invention is chosen so as to be an agent which solubilizes the active agent. The active agent-solubilizing vehicle may be made up of a single excipient, such as a solvent, or
20 of a mixture of excipients, such as those used for the formulation of an emulsion. By way of nonlimiting examples of excipients which may be used alone or as a mixture, mention may be made of water, solvents, diluents, and any excipient which can be used for the
25 formulation of an emulsion, of a milk, of a gel, of an ointment, or of a foaming composition. These excipients are compounds commonly used in the formulation of a

pharmaceutical composition. Preferably, the active agent-solubilizing excipients according to the invention are water, alcohols, polyols, ethers, esters, aldehydes, ketones, fatty acids and fatty alcohols, and
5 fatty esters. More preferably, the excipient used will be an alcohol. According to the invention, the term "alcohol" is intended to mean linear or branched aliphatic alcohols such as ethanol, propanol or isopropanol.

10 In a preferred embodiment according to the invention, the vehicle used will therefore be alcoholic.

According to the invention, the term "alcoholic vehicle" is intended to mean a vehicle
15 comprising at least 15% of alcohol, and preferably at least 25% of ethanol.

The pharmaceutical composition according to the invention may also contain inert additives or combinations of these additives, such as:

- 20 - wetting agents;
- flavour enhancers;
- preserving agents;
- stabilizers;
- moisture regulators;
- 25 - pH regulators;
- osmotic pressure modifiers;
- emulsifiers;

- UV-A and UV-B screening agents;
- propenetrating agents;
- antioxidants;
- and synthetic polymers.

5 Of course, those skilled in the art will take care to choose the possible compound(s) to be added to these compositions in such a way that the advantageous properties intrinsically associated with the present invention are not, or are not substantially, altered by
10 the envisaged addition.

 The composition according to the invention is more particularly intended for treating the skin and the mucous membranes, and may be provided in the form of ointments, creams, milks, salves, powders,
15 impregnated pads, syndets, solutions, gels, sprays, foams, suspensions, lotions, sticks, shampoos, pledgets or washing bases. It may also be provided in the form of suspensions of lipid or polymer vesicles or nanospheres or microspheres or polymer patches and
20 hydrogels to allow controlled release. This topical-application composition may be provided in anhydrous form, in aqueous form or in the form of an emulsion.

 The composition according to the invention showing improved penetration is preferably administered
25 in the form of a sprayable composition. In order to be sprayable, the compositions according to the invention will preferably have a viscosity of less than

50 centistokes, and more preferably less than
10 centistokes.

The sprayable form, or spray, can be obtained
by conventional formulation means known to those
5 skilled in the art. For example, the composition may be
sprayed by means of a mechanical spraying device which
pumps the composition from a container, bottle or
equivalent. The composition passes through a nozzle
which can be aimed directly at the desired site of
10 application. The nozzle can be chosen so as to apply
the composition in the form of a vaporization or of a
jet of droplets, according to techniques known to those
skilled in the art. According to the pharmaceutical
active agent chosen, the spraying mechanism must be
15 capable of always delivering the same amount of active
agent. The mechanisms for controlling the amount of
composition to be delivered by the spray are also known
to those skilled in the art.

Preferably, for the composition according to
20 the invention, a dosing spray bottle, for which the
application area and dose characteristics are
controlled and reproducible, will be used. For example,
the spray device used consists of a bottle equipped
with a 25 μ l dosing valve.

25 A subject of the present invention is also
the use of a composition according to the invention,
for producing a medicinal product intended for

treating:

- dermatological conditions associated with a keratinization disorder relating to differentiation and to proliferation, in particular common acne, comedo-
5 type acne, polymorphic acne, rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acne such as solar, drug-related or occupational acne,
- ichthyoses, ichthyosiform conditions, Darrier's disease, palmoplantar keratoderma, leukoplakia and
10 leukoplakiform conditions, and cutaneous or mucosal (oral) lichen,
- dermatological conditions with an inflammatory immunoallergic component, with or without a cell proliferation disorder, in particular cutaneous,
15 mucosal or ungual psoriasis, psoriatic rheumatism, cutaneous atopy, such as eczema, respiratory atopy or gingival hypertrophy,
- benign or malignant dermal or epidermal proliferations, of viral or nonviral origin, in
20 particular common warts, flat warts, epidermodysplasia verruciformis, oral or florid papillomatoses, and T lymphoma,
- proliferations which may be induced by ultraviolet light, in particular basal cell epithelioma and
25 spinocellular epithelioma,
- precancerous skin lesions, in particular keratoacanthomas,

- immune dermatoses, in particular lupus erythematosus,
- bullous immune diseases,
- collagen diseases, in particular scleroderma,
- 5 - dermatological or systemic conditions with an immunological component,
- skin disorders due to exposure to UV radiation, or light-induced or chronological ageing of the skin, or actinic keratoses and pigmentations, or any pathologies
- 10 associated with chronological or actinic ageing, in particular xerosis,
- sebaceous function disorders, in particular hyperseborrhoea acne or simple seborrhoea or seborrhoeic dermatitis,
- 15 - cicatrization disorders or stretch marks,
- pigmentation disorders, such as hyperpigmentation, melasma, hypopigmentation or vitiligo,
- lipid metabolism conditions, such as obesity, hyperlipidemia, non-insulin-dependant diabetes or
- 20 syndrome X,
- inflammatory conditions such as arthritis,
- cancerous or precancerous states,
- alopecia of various origins, in particular alopecia caused by chemotherapy or radiation,
- 25 - immune system disorders, such as asthma, type 1 diabetes mellitus, multiple sclerosis or other selective dysfunctions of the immune system, or

- cardiovascular system conditions such as arteriosclerosis or hypertension.

In a preferred embodiment of use of the composition, said composition will contain 0.3% of
5 (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol and will be used for producing a medicinal product intended to treat psoriasis.

The invention also relates to a process for improving the penetration of an active agent derived
10 from vitamin D, characterized in that a composition comprising the following, in a pharmaceutically acceptable vehicle, is applied to the skin:

- a) a therapeutically effective amount of an active agent derived from vitamin D,
 - 15 b) at least one volatile silicone,
 - c) a nonvolatile oily phase,
- said composition being applied in the form of a spray.

In fact, the applicant has discovered, surprisingly, that the penetration of an active agent,
20 and in particular of compounds derived from vitamin D, through the skin is improved by the composition according to the invention, even in the absence of excipients with propenetrating activity.

The expression "improvement in penetration
25 into the skin" is intended to mean a significant increase in penetration into the skin of at least a factor of 2, compared to formulations previously

produced on the market.

The penetration of the active agent is measured according to the protocol described in Example 4.

- 5 The following examples show, in a nonexhaustive manner, examples of formulation of the composition according to the invention and results of penetration into the skin.

Example 1:

The formulation is obtained by mixing the various compounds mentioned below until a homogeneous and clear solution is obtained.

5

Ingredients	Function	Spray A
(4E,6E)-7-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol	Active agent	0.3%
Hexamethyldisiloxane	Volatile silicone	60.0%
Paraffin oil	Nonvolatile oily phase	10.0%
Absolute ethanol	Solvent: excipient	qs 100%

Example 2:

The procedure used is the same as that in Example 1.

10

Ingredients	Function	Spray B
(4E,6E)-7-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol	Active agent	0.3%
Hexamethyldisiloxane	Volatile silicone	59.4%
Silicone gum	Silicone gum	0.6%
Paraffin oil	Nonvolatile oily phase	10.0%
Absolute ethanol	Solvent	qs 100%

Example 3:

The procedure used is the same as that in Example 1.

Ingredients	Function	Spray C
(4E,6E)-7-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol	Active agent	0.3%
Hexamethyldisiloxane	Volatile silicone	59.4%
Silicone gum	Silicone gum	0.6%
Paraffin oil	Nonvolatile oily phase	10.0%
Oleic acid	Propenetrating agent	5.0%
Butylhydroxytoluene (BHT)	Antioxidant	0.05%
Absolute ethanol	Solvent	qs 100%

5 Example 4: Study of the release/penetration *in vitro*,
on human skin, of (4E,6E)-7-[3-(3,4-bis-
bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-
3-ol contained in two different formulations, one of
which is sprayable according to the preferred
10 embodiment of the invention.

The first aim is to quantify the penetration
into the skin of the active agent formulated in both
formulations, *in vitro*, on human skin, after 16 hours
of application. A sprayable formula according to the
15 invention is compared with a composition in the form of
an ointment.

The exact compositions of the two formulations are given in Table 1 below.

TABLE 1

Ingredients	Function	Spray (in %)	Ointment (in %)
(4E, 6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)-phenyl]-3-ethylnona-4,6-dien-3-ol	Active agent	0.3	0.3
Hexamethyldisiloxane	Volatile silicone	59.40	
Silicone gum	Silicone gum	0.6	
Paraffin oil	Occlusive agent	10.00	5
Oleic acid	Propentrating agent	/	/
Propylene glycol	Propentrating agent		10.00
White petroleum jelly	Occlusive agent		76.94
Macrogol 2 stearyl ether			5
Disodium EDTA	Chelating agent		0.0065
DL-alpha-tocopherol	Antioxidant		0.12
BHT	Antioxidant		
Absolute ethanol	Solvent	qs 100%	
Water	Solvent		qs 100%

5

Experimental conditions: Percutaneous

absorption is evaluated by means of diffusion cells consisting of 2 compartments separated by human skin. The formulations were applied without occlusion for 16 hours. The formulations were applied at a rate of 10 mg of formulation per cm² (i.e. 30 micrograms of (4E, 6E)-7-

[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol). Throughout the duration of the study, the dermis is in contact with a recipient liquid which is not renewed as a function of time (static mode). At the end of the application period, the surface excess is removed and the distribution of the (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol is quantified in the various skin compartments and in the recipient liquid. The concentrations of (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol were quantified using an HPLC/MS/MS method conventionally known to those skilled in the art (LQ: 10 ng.mL⁻¹). The spray formula was applied using a spray bottle equipped with a 25 µl dosing valve.

The experimental results show that, whichever the formulation tested, the active agent is distributed mainly in the skin (epidermis, including stratum corneum, and dermis). The total amounts penetrated (stratum corneum + epidermis + dermis + recipient liquid) are:

	Application time: 16 hours
Spray Total amount having penetrated - µg	2.64 ± 0.50 µg

- % dose applied	9.2%
Ointment	
Total amount having penetrated	
- µg	0.63 ± 0.14 µg
- % dose applied	2.3%

Results:

The results show here that the spray formula according to the invention shows a four-fold increase in penetration of the active agent after 16 hours, compared with the ointment formula.

This result therefore indicates that the compositions according to the invention make it possible to obtain a significant improvement in penetration of an active agent derived from vitamin D compared with existing formulas.

The spray formulas as described therefore make it possible to do without the use of glycols, without decreasing skin penetration, and therefore show an additional advantage in terms of nonirritant potential versus the compositions comprising a high content of glycol.

CLAIMS

1. Composition comprising, in a pharmaceutically acceptable vehicle:
- a) a therapeutically effective amount of at least one pharmaceutical active agent,
 - b) at least one volatile silicone,
 - c) a nonvolatile oily phase,
- characterized in that the pharmaceutical active agent is derived from vitamin D and in that the composition is sprayable.
2. Composition according to Claim 1, characterized in that it comprises:
- a) between 0.0001 and 20% by weight of the active agent,
 - b) between 25 and 95% by weight of volatile silicone,
 - c) between 1 and 50% by weight of nonvolatile oily phase.
3. Composition according to either of Claims 1 and 2, characterized in that the vitamin D derivative is chosen from the following compounds:
- 6-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-2-methylhepta-3,5-dien-2-ol,
- 7-[3-(3,4-bishydroxymethylphenoxymethyl)phenyl]-3-ethyloctan-3-ol,
- 7-{3-[2-(3,4-bishydroxymethylphenyl)ethyl]phenyl}-3-ethylocta-4,6-dien-3-ol,

- 6-{3-[2-(3,4-bishydroxymethylphenyl)ethyl]phenyl}-2-methylhepta-3,5-dien-2-ol,
7-{3-[2-(3,4-bishydroxymethylphenyl)vinyl]phenyl}-3-ethylocta-4,6-dien-3-ol,
5 7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethyl-3-octanol,
4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylocta-4,6-dien-3-ol,
(4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-
10 ethylnona-4,6-dien-3-ol,
(E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethyloct-4-en-3-ol,
(E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethyloct-6-en-3-ol,
15 (E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethyloct-6-en-4-yn-3-ol,
(4E,6E)-7-[3-(3,4-bishydroxymethylphenoxymethyl)phenyl]-3-ethylocta-4,6-dien-3-ol,
20 (E)-7-[3-(3,4-bishydroxymethylphenoxymethyl)phenyl]-3-ethylnon-6-en-3-ol,
(E)-7-{3-[(3,4-bishydroxymethylbenzyl)methylamino]phenyl}-3-ethyloct-6-en-3-ol,
7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethyl-7-methyloctan-3-ol.
25

4. Composition according to one of Claims 1 to 3, characterized in that the pharmaceutical active

agent is (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol.

5. Composition according to one of Claims 1 to 4, characterized in that it contains between 0.01% and 2% by weight of compound derived from vitamin D.

6. Composition according to one of Claims 1 to 5, characterized in that the vehicle is an alcoholic vehicle.

10 7. Composition according to one of Claims 1 to 6, characterized in that the alcoholic vehicle comprises at least 15% of alcohol.

8. Composition according to one of Claims 1 to 7, characterized in that the alcoholic vehicle
15 comprises at least 25% of ethanol.

9. Composition according to one of Claims 1 to 8, characterized in that the volatile silicone is chosen from the group consisting of polydimethylcyclo-siloxanes and low molecular weight linear
20 polysiloxanes.

10. Composition according to one of Claims 1 to 9, characterized in that the volatile silicone is a linear polysiloxane of the hexamethyldisiloxane type.

11. Composition according to one of Claims 1 to 10, characterized in that it contains between 55 and
25 65% by weight of hexamethyldisiloxane.

12. Composition according to one of Claims 1

to 11, characterized in that the nonvolatile oily phase is a nonpolar oil.

13. Composition according to one of Claims 1 to 9, characterized in that the nonpolar oil is
5 paraffin oil.

14. Composition according to one of Claims 1 to 10, characterized in that it contains between 5 and 15% of paraffin oil.

15. Composition according to any one of the
10 preceding claims, characterized in that it also contains a silicone gum.

16. Composition according to any one of Claims 1 to 11, characterized in that it contains:

- 15 a) 0.3% of (4E,6E)-7-[3-(3,4-bishydroxy-methylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol,
- b) 60% of hexamethyldisiloxane,
- c) 10% of paraffin oil,
- d) 29.7% of ethanol.

17. Composition according to any one of
20 Claims 1 to 12, characterized in that it contains:

- a) 0.3% of (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol,
- b) 59.4% of hexamethyldisiloxane,
- c) 0.6% of silicone gum,
- 25 d) 10% of paraffin oil,
- e) 29.7% of ethanol.

18. Use of a composition according to any

one of Claims 1 to 15, for producing a medicinal product intended for treating:

- dermatological conditions associated with a keratinization disorder relating to differentiation and to proliferation, in particular common acne, comedo-type acne, polymorphic acne, rosacea, nodulocystic acne, acne conglobata, senile acne, and secondary acne such as solar, drug-related or occupational acne,
- ichthyoses, ichthyosiform conditions, Darrier's disease, palmoplantar keratoderma, leukoplakia and leukoplakiform conditions, and cutaneous or mucosal (oral) lichen,
- dermatological conditions with an inflammatory immunoallergic component, with or without a cell proliferation disorder, in particular cutaneous, mucosal or ungual psoriasis, psoriatic rheumatism, cutaneous atopy, such as eczema, respiratory atopy or gingival hypertrophy,
- benign or malignant dermal or epidermal proliferations, of viral or nonviral origin, in particular common warts, flat warts, epidermodysplasia verruciformis, oral or florid papillomatoses, and T lymphoma,
- proliferations which may be induced by ultraviolet light, in particular basal cell epithelioma and spinocellular epithelioma,
- precancerous skin lesions, in particular

- keratoacanthomas,
- immune dermatoses, in particular lupus erythematosus,
 - bullous immune diseases,
 - 5 - collagen diseases, in particular scleroderma,
 - dermatological or systemic conditions with an immunological component,
 - skin disorders due to exposure to UV radiation, or light-induced or chronological ageing of the skin, or
 - 10 actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing, in particular xerosis,
 - sebaceous function disorders, in particular hyperseborrhoea acne or simple seborrhoea or
 - 15 seborrhoeic dermatitis,
 - cicatrization disorders or stretch marks,
 - pigmentation disorders, such as hyperpigmentation, melasma, hypopigmentation or vitiligo,
 - lipid metabolism conditions, such as obesity,
 - 20 hyperlipidemia, non-insulin-dependant diabetes or syndrome X,
 - inflammatory conditions such as arthritis,
 - cancerous or precancerous states,
 - alopecia of various origins, in particular
 - 25 alopecia caused by chemotherapy or radiation,
 - immune system disorders, such as asthma, type 1 diabetes mellitus, multiple sclerosis or other

selective dysfunctions of the immune system, or

- cardiovascular system conditions such as arteriosclerosis or hypertension.

19. Use of a composition, according to
5 Claim 15, for treating psoriasis.

20. Process for improving the penetration of a pharmaceutical active agent derived from vitamin D, characterized in that a composition comprising the following, in a pharmaceutically acceptable vehicle is
10 applied to the skin:

a) a therapeutically effective amount of a compound derived from vitamin D,
b) at least one volatile silicone,
c) a nonvolatile oily phase,
15 said composition being applied in the form of a spray.

21. Process according to Claim 17, characterized in that the active agent is (4E,6E)-7-[3-(3,4-bishydroxymethylbenzyloxy)phenyl]-3-ethylnona-4,6-dien-3-ol, the volatile silicone is hexamethyl-
20 disiloxane, and the hydrophobic solvent is paraffin oil.

22. Process according to either of Claims 17 and 18, characterized in that the composition also comprises a silicone gum.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/014085

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/09 A61K47/14 A61K47/24 A61K47/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	<p>US 6 538 039 B2 (LAURENT PHILIPPE) 25 March 2003 (2003-03-25) cited in the application</p> <p>column 2, line 66 - column 3, line 13 column 3, line 16 - line 31 column 3, line 45 - column 4, line 31 examples 23-26 claims 1-13 column 2, line 12 - line 15 column 3, line 32 - line 44</p> <p style="text-align: center;">----- -/-</p>	<p>1,2, 5-11,18, 20 3,4, 12-15, 19,21,22</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 March 2005

Date of mailing of the international search report

13/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Giacobbe, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/014085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 97/15295 A (LAFON LABOR ; LAURENT PHILIPPE (FR)) 1 May 1997 (1997-05-01) page 2, line 14 - page 3, line 19 page 3, line 23 - line 28 abstract page 4, line 26 - page 5, line 14 page 5, line 15 - page 6, line 2	1,2, 5-11,18, 20 3,4, 12-15, 19,21,22
X Y	EP 0 512 814 A (UNILEVER PLC ; UNILEVER NV (NL)) 11 November 1992 (1992-11-11) examples 1-4,7-11,14 page 11, line 56 page 3, line 40	1,5,6,9, 10,18,20 2-4, 11-14, 16,17, 21,22
Y	US 4 889 845 A (LAWTER JAMES R ET AL) 26 December 1989 (1989-12-26) claims 1-7 & EP 0 249 193 A (AMERICAN CYANAMID CO) 16 December 1987 (1987-12-16) abstract	1-22
Y	PATENT ABSTRACTS OF JAPAN vol. 0143, no. 90 (C-0751), 23 August 1990 (1990-08-23) & JP 02 145512 A (SHIN ETSU CHEM CO LTD), 5 June 1990 (1990-06-05) abstract	1-22
Y	US 4 678 663 A (WORTZMAN MITCHELL S ET AL) 7 July 1987 (1987-07-07) column 2, line 35 - line 55 column 2, line 62 - column 3, line 2 table 1 examples 1-15	1-22
Y	EP 0 966 972 A (DOW CORNING SA) 29 December 1999 (1999-12-29) cited in the application paragraph '0005! - paragraph '0007! paragraph '0010! paragraph '0013! - paragraph '0015! paragraph '0019! - paragraph '0020!	12,22
Y	FR 2 785 284 A (GALDERMA RES & DEV) 5 May 2000 (2000-05-05) cited in the application page 4, line 10 - page 6, line 21 -/--	3,16,17, 19,21

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/014085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00/26167 A (GALDERMA RESEARCH & DEVELOPMENT, S.N.C; BERNARDON, JEAN-MICHEL) 11 May 2000 (2000-05-11) example 108	1-22
P,X	WO 2004/039390 A (GOULBOURNE MARY J) 13 May 2004 (2004-05-13) page 1, paragraph 1 - paragraph 7	1,9,13, 14,18
P,A	WO 2004/069134 A (GALDERMA RESEARCH & DEVELOPMENT, S.N.C; ASTRUC, FANNY; ORSONI, SANDRIN) 19 August 2004 (2004-08-19) the whole document	1-22

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP2004/014085

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6538039	B2	15-08-2002	FR 2719220 A1 03-11-1995
		US 2002111387 A1 15-08-2002	
		AT 210430 T 15-12-2001	
		AU 680731 B2 07-08-1997	
		AU 1767595 A 16-11-1995	
		CA 2148112 A1 30-10-1995	
		DE 69524470 D1 24-01-2002	
		DE 69524470 T2 23-05-2002	
		DK 679392 T3 08-04-2002	
		EP 0679392 A1 02-11-1995	
		ES 2169746 T3 16-07-2002	
		HK 1008658 A1 26-04-2002	
		HU 75251 A2 28-05-1997	
		JP 2740465 B2 15-04-1998	
		JP 8059456 A 05-03-1996	
		KR 233770 B1 01-12-1999	
		NZ 272014 A 26-05-1997	
		PT 679392 T 31-05-2002	
		TW 448050 B 01-08-2001	
		ZA 9503392 A 28-10-1996	
WO 9715295	A	01-05-1997	FR 2740038 A1 25-04-1997
		AT 220899 T 15-08-2002	
		AU 713474 B2 02-12-1999	
		AU 7306396 A 15-05-1997	
		CA 2235346 A1 01-05-1997	
		CN 1202819 A 23-12-1998	
		DE 69622574 D1 29-08-2002	
		DE 69622574 T2 19-12-2002	
		DK 855907 T3 11-11-2002	
		EP 0855907 A1 05-08-1998	
		ES 2179213 T3 16-01-2003	
		WO 9715295 A1 01-05-1997	
		HU 9802983 A2 28-06-1999	
		JP 2000500436 T 18-01-2000	
		NZ 320337 A 23-12-1998	
		PT 855907 T 29-11-2002	
		US 6325990 B1 04-12-2001	
EP 0512814	A	11-11-1992	EP 0512814 A1 11-11-1992
US 4889845	A	26-12-1989	US 5280018 A 18-01-1994
		AU 600277 B2 09-08-1990	
		AU 7411687 A 10-12-1987	
		DK 294487 A 10-12-1987	
		EP 0249193 A2 16-12-1987	
		FI 872553 A 10-12-1987	
		HU 49284 A2 28-09-1989	
		JP 63045221 A 26-02-1988	
		NZ 220628 A 28-08-1990	
		ZA 8704141 A 25-05-1988	
EP 0249193	A	16-12-1987	AU 600277 B2 09-08-1990
		AU 7411687 A 10-12-1987	
		DK 294487 A 10-12-1987	
		EP 0249193 A2 16-12-1987	
		FI 872553 A 10-12-1987	
		HU 49284 A2 28-09-1989	

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP2004/014085

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0249193	A		JP 63045221 A NZ 220628 A US 4889845 A US 5280018 A ZA 8704141 A	26-02-1988 28-08-1990 26-12-1989 18-01-1994 25-05-1988
JP 02145512	A	05-06-1990	NONE	
US 4678663	A	07-07-1987	AT 48940 T CA 1234759 A1 DE 3574928 D1 DK 456985 A EP 0172228 A1 FI 853431 A , B, JP 61501091 T NO 853941 A NO 165137 B WO 8503434 A1 US 4725429 A US 4727088 A US 4738956 A	15-01-1990 05-04-1988 01-02-1990 07-10-1985 26-02-1986 09-09-1985 29-05-1986 04-10-1985 24-09-1990 15-08-1985 16-02-1988 23-02-1988 19-04-1988
EP 0966972	A	29-12-1999	EP 0966972 A1 DE 69911505 D1 DE 69911505 T2 JP 2000053588 A	29-12-1999 30-10-2003 01-07-2004 22-02-2000
FR 2785284	A	05-05-2000	FR 2785284 A1 AT 288410 T AU 762056 B2 AU 6347699 A BR 9915247 A CA 2348725 A1 CN 1332711 A DE 69923573 D1 EP 1124779 A1 WO 0026167 A1 HU 0104195 A2 JP 2002528523 T NO 20012116 A NZ 511239 A PL 347548 A1 RU 2208601 C2 US 6689922 B1 ZA 200103186 A	05-05-2000 15-02-2005 19-06-2003 22-05-2000 30-10-2001 11-05-2000 23-01-2002 10-03-2005 22-08-2001 11-05-2000 28-03-2002 03-09-2002 02-07-2001 28-11-2003 08-04-2002 20-07-2003 10-02-2004 22-11-2001
WO 0026167	A	11-05-2000	FR 2785284 A1 AT 288410 T AU 762056 B2 AU 6347699 A BR 9915247 A CA 2348725 A1 CN 1332711 A DE 69923573 D1 EP 1124779 A1 WO 0026167 A1 HU 0104195 A2 JP 2002528523 T	05-05-2000 15-02-2005 19-06-2003 22-05-2000 30-10-2001 11-05-2000 23-01-2002 10-03-2005 22-08-2001 11-05-2000 28-03-2002 03-09-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/014085

PC/EI 2004/014085

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0026167	A	NO 20012116 A NZ 511239 A PL 347548 A1 RU 2208601 C2 US 6689922 B1 ZA 200103186 A	02-07-2001 28-11-2003 08-04-2002 20-07-2003 10-02-2004 22-11-2001	
WO 2004039390	A	13-05-2004	US 2004013744 A1 WO 2004039390 A1	22-01-2004 13-05-2004
WO 2004069134	A	19-08-2004	FR 2850575 A1 WO 2004069134 A2	06-08-2004 19-08-2004